Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1992 1
1993 1
2002 1
2003 4
2004 2
2006 1
2008 1
2010 1
2012 2
2013 1
2014 1
2015 2
2016 2
2017 2
2018 1
2020 1
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Giovannoni G, et al. Among authors: borsi l. Mult Scler. 2023 May;29(6):719-730. doi: 10.1177/13524585231161494. Epub 2023 Apr 3. Mult Scler. 2023. PMID: 37012898 Free PMC article.
Primary objective includes evaluation of long-term mobility (no wheelchair use in the 3 months prior to first visit in CLASSIC-MS and not bedridden at any time since last parent study dose (LPSD), i.e. Expanded Disability Status Scale (EDSS) score <7). Secondary objecti …
Primary objective includes evaluation of long-term mobility (no wheelchair use in the 3 months prior to first visit in CLASSIC-MS and not be …
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Borsi E, Mazzocchetti G, Dico AF, Vigliotta I, Martello M, Poletti A, Solli V, Armuzzi S, Taurisano B, Kanapari A, Pistis I, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Rocchi S, Rizzello I, Cavo M, Terragna C. Borsi E, et al. Clin Exp Med. 2023 Dec;23(8):5227-5239. doi: 10.1007/s10238-023-01205-y. Epub 2023 Oct 10. Clin Exp Med. 2023. PMID: 37815734 Free PMC article.
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases.
Vigliotta I, Armuzzi S, Barone M, Solli V, Pistis I, Borsi E, Taurisano B, Mazzocchetti G, Martello M, Poletti A, Sartor C, Rizzello I, Pantani L, Tacchetti P, Papayannidis C, Mancuso K, Rocchi S, Zamagni E, Curti A, Arpinati M, Cavo M, Terragna C. Vigliotta I, et al. Among authors: borsi e. Front Oncol. 2022 Oct 6;12:1001048. doi: 10.3389/fonc.2022.1001048. eCollection 2022. Front Oncol. 2022. PMID: 36276072 Free PMC article.
METHODS: For each BM sample, cells populations with a well-known distribution in BM and peripheral blood - e.g., mast cells (MC), immature (IG) and mature granulocytes (N) - have been studied by FC and quantified alongside the BM differential count. ...
METHODS: For each BM sample, cells populations with a well-known distribution in BM and peripheral blood - e.g., mast cells (MC), imm …
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Vigliotta I, Rizzello I, Rocchi S, Armuzzi S, Testoni N, Marzocchi G, Martinelli G, Cavo M, Terragna C. Martello M, et al. Among authors: borsi e. Blood Cancer J. 2022 Jan 26;12(1):15. doi: 10.1038/s41408-022-00610-y. Blood Cancer J. 2022. PMID: 35082295 Free PMC article.
[Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
Csáki C, Ferencz T, Koós R, Schuler D, Borsi J. Csáki C, et al. Among authors: borsi j. Orv Hetil. 1993 Jun 20;134(25):1363-7. Orv Hetil. 1993. PMID: 8332356 Review. Hungarian.
Based on their selectivity 5-HT3 antagonist are free from extrapyramidal side effects, a major problem in children in the case of currently used dopamine receptor antagonists (e.g. metoclopramide). In this study ondansetron was tested as antiemetic in 33 children with mali …
Based on their selectivity 5-HT3 antagonist are free from extrapyramidal side effects, a major problem in children in the case of currently …
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.
Mancuso K, Zamagni E, Solli V, Gabrielli L, Leone M, Pantani L, Rocchi S, Rizzello I, Tacchetti P, Ghibellini S, Favero E, Ursi M, Talarico M, Barbato S, Kanapari A, Bigi F, Puppi M, Terragna C, Borsi E, Martello M, Poletti A, Scatà A, Nepoti G, Ruffini B, Lazzarotto T, Cavo M. Mancuso K, et al. Among authors: borsi e. Front Oncol. 2023 May 25;13:1208741. doi: 10.3389/fonc.2023.1208741. eCollection 2023. Front Oncol. 2023. PMID: 37305577 Free PMC article.
Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn's Disease patients: A retrospective analysis using German claims data.
Zhuleku E, Antolin-Fontes B, Borsi A, Nissinen R, Bravatà I, Barthelmes JN, Le Bars M, Lee J, Passey A, Maywald U, Deiters B, Bokemeyer B, Wilke T, Ghiani M. Zhuleku E, et al. Among authors: borsi a. Therap Adv Gastroenterol. 2022 Nov 4;15:17562848221130554. doi: 10.1177/17562848221130554. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 36353736 Free PMC article.
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.
Martello M, Solli V, Termini R, Kanapari A, Remondini D, Borsi E, Poletti A, Armuzzi S, Taurisano B, Vigliotta I, Mazzocchetti G, Zamagni E, Merlotti A, Tacchetti P, Pantani L, Rocchi S, Rizzello I, Mancuso K, Cavo M, Terragna C. Martello M, et al. Among authors: borsi e. Int J Mol Sci. 2022 Oct 18;23(20):12450. doi: 10.3390/ijms232012450. Int J Mol Sci. 2022. PMID: 36293315 Free PMC article.
In addition, the plasma cells' differentiation status determined by ddPCR was further confirmed by other techniques, such as flow cytometry, allowing the identification of patients with immature plasma cells' phenotype (i.e., expressing CD19+/CD81+ markers) upregulating HH …
In addition, the plasma cells' differentiation status determined by ddPCR was further confirmed by other techniques, such as flow cytometry, …
32 results